Clinical trial
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
NCT01794663 is registered in ClinicalTrials.gov with Opsona Therapeutics Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
- Lead sponsor
- Opsona Therapeutics Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2012
- Completion date
- June 30, 2016
- Enrollment
- 252 (actual)
- Sites
- 50
Conditions
As the registry lists them; a condition with its own page is linked.